The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of online CME on clinicians’ ability to utilize immunotherapy in unique populations of patients with NSCLC.
 
Michelle Arielle Worst
No Relationships to Disclose
 
Andrew Small
No Relationships to Disclose
 
Amy Furedy
No Relationships to Disclose
 
Cong Zhang
No Relationships to Disclose
 
Meng Yuan
No Relationships to Disclose
 
Sukhbir Bahra
No Relationships to Disclose
 
Stephen V. Liu
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Candel Therapeutics; Catalyst Pharmaceuticals; Daiichi Sankyo/UCB Japan; Elevation Oncology; Genentech; Gilead Sciences; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Merus; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; RAPT Therapeutics; Regeneron; Revolution Medicines; Sanofi; Takeda
Research Funding - Abbvie (Inst); Alkermes (Inst); Elevation Oncology (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Merus (Inst); Nuvalent, Inc. (Inst); OSE Immunotherapeutics (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Turning Point Therapeutics (Inst)
 
Jared Weiss
Stock and Other Ownership Interests - Achilles Therapeutics (I); Enfuego Therapeutics; Lyell Immunopharma; Nektar; Nuvalent, Inc.; Vertex; Vesselon
Consulting or Advisory Role - abbvie; Amgen; AstraZeneca; BeiGene; EMD Serono; G1 Therapeutics; Genentech; Genmab; Gilead Sciences; Jounce Therapeutics; Merck; Nanobiotix; PDS Biotechnology; Regeneron; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); G1 Therapeutics (Inst); Immunicum (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); PDS Biotechnology (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics